CATEGORY AND TAGS:
Tirzepatide Peptide raw powder, raw Tirzepatide peptide, Tirzepatide Dosage Dose, buy Tirzepatide 2mg, Tirzepatide 6mg, Tirzepatide 16mg, Tirzepatide 10mg red top, Tirzepatide cycle, Tirzepatide factory price, research chemical Tirzepatide peptide, Tirzepatide 10vials, where to buy Tirzepatide, Tirzepatide peptide supplier, Tirzepatide online store, buy Tirzepatide Canada, Tirzepatide Poland, Tirzepatide USA, human growth peptide Tirzepatide, Tirzepatide manufacturer, Tirzepatide raw powder for sale, Tirzepatide effects, Tirzepatide fat loss, Tirzepatide 10kits price
Tirzepatide Specifications
CAS Number: 2023788-19-2
Molecular Formula: C225H348N48O68
Molecular Weight: 4813.527 g/mol
Purity: 99%
Tirzepatide Description
Tirzepatide is a synthetic analogue of gastric inhibitory polypeptide (GIP) that was developed for its ability to stimulate insulin release and thus address both type 2 diabetes and non-alcoholic fatty liver disease. Made up of 39 amino acids, the relatively large Tirzepatide stimulates the release of insulin from the pancreas by binding to both GIP and GLP-1 (glucagon-like peptide-1) receptors. Taken over longer periods of time, Tirzepatide increases adiponectin levels by as much as 26% as well[1]. Research shows that Tirzepatide reduces feelings of hunger, lowers insulin levels, and increases insulin sensitivity. Taken together, these effects cause significant weight loss of 11 kg (25 lbs), improve glucose tolerance, decrease fat (adipose) tissue, and reduce cardiovascular risk.
Tirzepatide Application
Tirzepatide is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems.
Mechanism of action It works to stimulate first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner. Tirzepatide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake, 4 and reduce body weight in patients with type 2 diabetes.
Pharmacology Tirzepatide is a once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist that integrates the actions of both incretins into a single novel molecule. GIP is a hormone that may complement the effects of GLP-1 receptor agonists. In preclinical models, GIP has been shown to decrease food intake and increase energy expenditure therefore resulting in weight reductions, and when combined with GLP-1 receptor agonism, may result in greater effects on markers of metabolic dysregulation such as body weight, glucose and lipids. Tirzepatide is in phase 3 development for adults with obesity or overweight with weight-related comorbidity and is currently under regulatory review as a treatment for adults with type 2 diabetes. It is also being studied as a potential treatment for non-alcoholic steatohepatitis (NASH) and heart failure with preserved ejection fraction (HFpEF). Studies of tirzepatide in obstructive sleep apnea (OSA) and in morbidity/mortality in obesity are planned as well.
